Reneuron Group (RENE)

 

Latest News

Capital Markets Event

RNS Number: 3433O ReNeuron Group plc 17 May 2018 17 May 2018 AIM: RENE ReNeuron Group plc ("ReNeuron" or the "Company") Capital Markets Event ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, i s today, as previously announced, hosting a capital markets event focused on the Company's exoso...

Exosome data presented at ISCT conference

RNS Number: 1028N ReNeuron Group plc 04 May 2018 AIM: RENE 4 May 2018 ReNeuron Group plc ("ReNeuron" or the "Company") Exosome data presented at ISCT conference Positive pre-clinical data in cancer with ReNeuron's ExoPr0 exosome therapy candidate accepted for podium presentation at the 2018 International Society of Cell Therapy (ISCT) annual m...

Is this small-cap worth testing?

This stem cell research company has experienced a volatile time of late. Alistair Strang goes under the microscope to see ho...

Trends and Targets for 3/05/2018

RENEURON GROUP (LSE:RENE) Share price movements here risk proving similar to the new Marvel Avengers movie...

All News

DateHeadlineSource
17-05-18Capital Markets EventRNS
04-05-18Exosome data presented at ISCT conferenceRNS
03-05-18Is this small-cap worth testing?Interactive Investor
02-05-18Trends and Targets for 3/05/2018Trends and Targets
30-04-18Capital Markets Event and WebcastRNS
19-04-18ReNeuron wins grant for retinal cell therapy developmentStockMarketWire
19-04-18Wins grant for retinal cell therapy developmentRNS
10-04-18Appointment of US-based Chief Medical OfficerRNS
26-03-18Product Development UpdateRNS
01-03-18Block Listing Review and TVRRNS
16-02-18Block Listing ApplicationRNS
13-02-18Positive pre-clinical data in nerve injuryRNS
26-01-18ReNeuron presents treatment trial resultsStockMarketWire
26-01-18Phase II stroke data presented at AHA conferenceRNS
23-01-18ReNeuron shareholders approval capital re-organisationStockMarketWire
11-01-18Further re Share Capital ReorganisationRNS
05-01-18ReNeuron Group plans share reductionStockMarketWire
05-01-18Proposed Share Capital ReorganisationRNS
14-12-17ReNeuron losses widenStockMarketWire
14-12-17Interim resultsRNS
14-12-17Stroke clinical trial regulatory approval in USRNS
08-12-17ReNeuron Group opens Boston officeStockMarketWire
08-12-17ReNeuron opens US officeRNS
13-11-17Notification of Interim ResultsRNS
08-11-17ReNeuron clinical trial enters next phaseStockMarketWire
08-11-17Retinal disease clinical trial moves into Phase IIRNS
31-10-17ReNeuron reports positive trial dataStockMarketWire
31-10-17Positive stroke clinical data & regulatory updateRNS
27-10-17ReNeuron wins Welsh grantStockMarketWire
27-10-17Wins further UK grantRNS
11-10-17PDMR Interest in Shares and Share OptionsRNS
09-10-17Presentation of positive pre-clinical dataRNS
12-09-17Directors' Interest in Shares and Share OptionsRNS
06-09-17Result of AGMRNS
06-09-17AGM Trading UpdateRNS
01-09-17Non-executive Director AppointmentRNS
01-09-17Block Listing Review and TVRRNS
07-08-17Neil Woodford 'very confident' he can deliver 10%-plus yearly returnsMoney Observer
07-08-17Posting of Annual Report and Notice of AGMRNS
04-08-17Second Price Monitoring ExtnRNS

RSS feeds

  • Editorial news feed for LSE:RENE Editorial
  • Regulatory news feed for LSE:RENE Regulatory